Gentherm Officially Launches New Product with KUKA Home in Asia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy THRM?
Gentherm announced the official product launch with KUKA Home in Asia, extending Gentherm's scalable technology platforms beyond automotive into home furniture applications. The launch is a result of our previous announcement in October 2025. These programs highlight Gentherm's role as a collaborative innovation partner, working closely with KUKA from concept through production. Gentherm combines consumer-informed wellness insights and real-world integration expertise with scalable roadmaps that help partners bring differentiated comfort experiences to market and communicate that value to end customers. For these specific KUKA programs, KUKA has chosen to feature 'Enhanced Comfort by Gentherm' as the co-branded program identifier, reinforcing Gentherm's role as a value-adding innovation partner.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THRM
Wall Street analysts forecast THRM stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 28.260
Low
42.00
Averages
43.33
High
44.00
Current: 28.260
Low
42.00
Averages
43.33
High
44.00
About THRM
Gentherm Incorporated is a provider of thermal management and pneumatic comfort technologies. The Company operates in two segments: Automotive and Medical. The Automotive reporting segment comprises global automotive businesses, including the design, development, manufacturing and sales of its automotive climate and comfort solutions (including Climate Control Seats, Climate Control Interiors, lumbar and massage comfort solutions and electronic solutions for climate and comfort technologies), valve system solutions and other automotive products. The Medical reporting segment comprises the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Product Introduction: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement, addressing dual challenges faced during surgeries, which is expected to significantly improve patient experience and safety in surgical settings.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification to the FDA for the ThermAffyx™ earlier this year, with clearance anticipated in May, paving the way for market entry and enhancing competitive positioning.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, indicating strong growth potential and strategic importance in expanding its footprint in the medical device market, particularly in innovations related to patient safety.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Medical Device: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement challenges into a single solution, addressing a critical clinical need and expected to significantly improve patient safety during surgical procedures.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification for ThermAffyx™ to the FDA earlier this year, with clearance anticipated in May, paving the way for the product's market introduction.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, highlighting its strong potential and growth prospects in the medical device market.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics: As analysts revise their outlook on THRM stock, investors may consider buying or selling, potentially impacting its market performance and liquidity, thereby increasing market uncertainty.
- Impact of Rating Changes: Changes in analyst ratings often have a direct effect on stock prices, prompting investors to closely monitor these shifts to timely adjust their investment strategies and optimize their portfolios.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors should reference these ratings for a more comprehensive market view.
See More
Gentherm Q4 2025 Earnings Call Insights
- Strategic Expansion: Gentherm's planned merger with Modine Performance Technologies is expected to elevate its market size from $2.6 billion to over $3.5 billion, showcasing the company's strong potential for diversification, particularly in the medical and Home & Office sectors.
- Financial Performance: The company achieved record revenue of $1.5 billion in 2025, reflecting a 2.9% year-over-year increase, with adjusted EBITDA of $175 million, or 11.7% of sales, demonstrating stability in core operations despite foreign exchange impacts.
- Future Outlook: Management anticipates revenue for 2026 to be between $1.5 billion and $1.6 billion, representing approximately 3% growth at the midpoint, and aims for $1.7 billion in 2027, reflecting confidence in market penetration.
- Market Opportunities: Gentherm expects revenue from Home & Office and medical markets to reach between $50 million and $100 million by 2028, indicating significant growth potential in non-automotive sectors, particularly with the launch of the ThermAffyx system to accelerate medical revenue growth.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying CAKE stock should pay attention to the latest insights from analysts to make more informed investment decisions.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and data support.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Product Introduction: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement, addressing dual challenges faced during surgeries, which is expected to significantly improve patient experience and safety in surgical settings.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification to the FDA for the ThermAffyx™ earlier this year, with clearance anticipated in May, paving the way for market entry and enhancing competitive positioning.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, indicating strong growth potential and strategic importance in expanding its footprint in the medical device market, particularly in innovations related to patient safety.
See More
Gentherm Partners with KNB to Launch Innovative Medical Device
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Medical Device: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement challenges into a single solution, addressing a critical clinical need and expected to significantly improve patient safety during surgical procedures.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification for ThermAffyx™ to the FDA earlier this year, with clearance anticipated in May, paving the way for the product's market introduction.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, highlighting its strong potential and growth prospects in the medical device market.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics: As analysts revise their outlook on THRM stock, investors may consider buying or selling, potentially impacting its market performance and liquidity, thereby increasing market uncertainty.
- Impact of Rating Changes: Changes in analyst ratings often have a direct effect on stock prices, prompting investors to closely monitor these shifts to timely adjust their investment strategies and optimize their portfolios.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors should reference these ratings for a more comprehensive market view.
See More
Gentherm Q4 2025 Earnings Call Insights
- Strategic Expansion: Gentherm's planned merger with Modine Performance Technologies is expected to elevate its market size from $2.6 billion to over $3.5 billion, showcasing the company's strong potential for diversification, particularly in the medical and Home & Office sectors.
- Financial Performance: The company achieved record revenue of $1.5 billion in 2025, reflecting a 2.9% year-over-year increase, with adjusted EBITDA of $175 million, or 11.7% of sales, demonstrating stability in core operations despite foreign exchange impacts.
- Future Outlook: Management anticipates revenue for 2026 to be between $1.5 billion and $1.6 billion, representing approximately 3% growth at the midpoint, and aims for $1.7 billion in 2027, reflecting confidence in market penetration.
- Market Opportunities: Gentherm expects revenue from Home & Office and medical markets to reach between $50 million and $100 million by 2028, indicating significant growth potential in non-automotive sectors, particularly with the launch of the ThermAffyx system to accelerate medical revenue growth.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying CAKE stock should pay attention to the latest insights from analysts to make more informed investment decisions.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and data support.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
